{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:16:15Z","timestamp":1762870575846,"version":"build-2065373602"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das RS3PE(\u201eremitting seronegative symmetric synovitis with pitting edema\u201c)-Syndrom ist eine seltene entz\u00fcndlich rheumatische Erkrankung des \u00e4lteren Menschen, die auch paraneoplastisch auftreten kann. Leitsymptom ist die rasch progrediente, symmetrische \u00f6demat\u00f6se Schwellung beider H\u00e4nde, teils auch beider F\u00fc\u00dfe, begleitet durch (Teno-)Synovitiden. Autoimmunserologien (Rheumafaktoren, Antik\u00f6rper gegen zyklische citrullinierte Peptide, antinukle\u00e4re Antik\u00f6rper) bleiben typischerweise negativ. Wird die Diagnose eines RS3PE-Syndroms gestellt, sollten bislang ausgebliebene altersentsprechende Malignom-Screening-Untersuchungen nachgeholt werden. Zudem sollten eine ausf\u00fchrliche Anamnese und k\u00f6rperliche Untersuchung mit der Frage nach Hinweisen f\u00fcr eine Neoplasie durchgef\u00fchrt werden, gegebenenfalls gefolgt von weiteren Untersuchungen. Das RS3PE-Syndrom spricht typischerweise exzellent auf eine Therapie mit Glukokortikoiden an. H\u00e4ufig wird eine medikamentenfreie Remission erreicht, teils ist eine Therapie mit DMARDs (\u201edisease-modifying antirheumatic drugs\u201c) notwendig.<\/jats:p>","DOI":"10.1007\/s00393-025-01704-1","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:21:38Z","timestamp":1756297298000},"page":"734-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das RS3PE-Syndrom\u00a0\u2013 eine seltene fakultative Paraneoplasie","RS3PE syndrome\u2014A rare facultative paraneoplasm"],"prefix":"10.1007","volume":"84","author":[{"given":"Andriko","family":"Palmowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hildrun","family":"Haibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"3","key":"1704_CR1","first-page":"404","volume":"34","author":"P Karmacharya","year":"2016","unstructured":"Karmacharya\u00a0P, Donato\u00a0AA, Aryal\u00a0MR (2016) et\u00a0al. RS3PE revisited: a\u00a0systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol 34(3):404\u2013415","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1704_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1067-2516(00)80021-6","volume":"39","author":"JA Finnell","year":"2000","unstructured":"Finnell\u00a0JA, Cuesta\u00a0IA (2000) Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: A\u00a0review of the literature and a\u00a0report of three cases. J\u00a0Foot Ankle Surg 39(3):189\u2013193. https:\/\/doi.org\/10.1016\/S1067-2516(00)80021-6","journal-title":"J Foot Ankle Surg"},{"issue":"2","key":"1704_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1024\/0301-1526.34.2.144","volume":"34","author":"I Coiteux","year":"2005","unstructured":"Coiteux\u00a0I, Depairon\u00a0M, Hayoz\u00a0D (2005) Pitting edema of the four extremities of rapid appearance. Vasa 34(2):144\u2013146. https:\/\/doi.org\/10.1024\/0301-1526.34.2.144","journal-title":"Vasa"},{"issue":"3","key":"1704_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/ard.58.3.142","volume":"58","author":"J Dudler","year":"1999","unstructured":"Dudler\u00a0J, Gerster\u00a0JC, So\u00a0A (1999) Polyarthritis and pitting oedema. Ann Rheum Dis 58(3):142\u2013147. https:\/\/doi.org\/10.1136\/ard.58.3.142","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1704_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/annrheumdis-2015-eular.3312","volume":"74","author":"M Calis","year":"2015","unstructured":"Calis\u00a0M, Cuce\u00a0I, Akgul\u00a0O et\u00a0al (2015) AB1034 The Treatment Approach for the Management of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome. Ann Rheum Dis 74(2):1244\u20131244. https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.3312","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1704_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.36401\/jipo-20-2","volume":"3","author":"ST Kim","year":"2020","unstructured":"Kim\u00a0ST, Murphy\u00a0WA Jr., Aparicio\u00a0A et\u00a0al (2020) RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a\u00a0Patient With Metastatic Prostate Cancer. J\u00a0Immunother Precis Oncol 3(3):128\u2013132. https:\/\/doi.org\/10.36401\/jipo-20-2","journal-title":"J Immunother Precis Oncol"},{"issue":"1","key":"1704_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/14397595.2016.1192744","volume":"27","author":"T Origuchi","year":"2017","unstructured":"Origuchi\u00a0T, Arima\u00a0K, Umeda\u00a0M et\u00a0al (2017) Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. Mod Rheumatol 27(1):150\u2013154. https:\/\/doi.org\/10.1080\/14397595.2016.1192744","journal-title":"Mod Rheumatol"},{"issue":"19","key":"1704_CR8","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1001\/jama.1985.03360190069027","volume":"254","author":"DJ McCarty","year":"1985","unstructured":"McCarty\u00a0DJ, O\u2019Duffy\u00a0JD, Pearson\u00a0L et\u00a0al (1985) Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254(19):2763\u20132767","journal-title":"JAMA"},{"issue":"11","key":"1704_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/ard.58.11.722","volume":"58","author":"M GUM\u00c1","year":"1999","unstructured":"GUM\u00c1\u00a0M, CASADO\u00a0E, TENA\u00a0X et\u00a0al (1999) RS3PE: six years later. Ann Rheum Dis 58(11):722\u2013723. https:\/\/doi.org\/10.1136\/ard.58.11.722","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01704-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01704-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01704-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:06:19Z","timestamp":1762869979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01704-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01704-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"7 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Palmowski, R.\u00a0Biesen, P.\u00a0Hoff, M.\u00a0Lehmann, R.\u00a0Somasundaram, F.\u00a0Buttgereit und H.\u00a0Haibel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}